AbbVie Invests $195 Million in New North Chicago API Manufacturing Site
AbbVie is investing $195 million to build a new active pharmaceutical ingredient (API) manufacturing facility at its North Chicago, Illinois site1234.
Construction will begin in fall 2025, with the facility expected to become operational in 2027124.
The new site will enhance AbbVie's chemical synthesis capacities and support the domestic production of current and next-generation therapies in neuroscience, immunology, and oncology14.
This expansion is part of AbbVie’s broader plan to invest over $10 billion in U.S. manufacturing and reinforces its long-term presence in Illinois, where the company supports over 11,000 jobs1.
Active pharmaceutical ingredient production at this facility will boost AbbVie’s U.S.-based manufacturing and contract manufacturing capabilities1.
The project aims to help maintain U.S. leadership in pharmaceutical innovation and ensure the supply of critical medicines for patients1.
Sources:
1. https://pharmasource.global/content/news/cdmo-news/abbvie-invests-195-million-to-expand-api-manufacturing-in-north-chicago/
2. https://www.powderbulksolids.com/pharmaceuticals-medical-products/abbvie-injects-195-million-into-us-active-pharmaceutical-ingredient-manufacturing
3. https://www.fiercepharma.com/manufacturing/abbvie-plans-195m-api-plant-illinois-part-us-investment-campaign